

October 22, 2019

To,
The Manager
Listing Department,
The National Stock Exchange of India Limited
Exchange Plaza,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400051

Dear Sir/Madam,

**Trading Symbol: ZOTA** 

**Sub: Product Registration in Turkmenistan** 

Ref.: Regulation 30(6) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 30(6) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 this is to inform you that we, Zota Health Care Limited (the "Company") have received product registration license for below mentioned one product from Turkmenistan.

Sr. No.	Name of Product	Therapeutic Category
1	PYLOZED KIT [Each combikit contains Esomeprazole 20mg (2 Tabs.), Clarithromycin 500mg (2 Tabs.) & Tinidazone 500mg (2 Tabs.)]	Kit for GI Infection

We have received license for the aforementioned product for the validity period of five years, license for the product is also renewable. Company shall start exporting this product in Turkmenistan very soon.

This is for your information and record.

Thanking you,

Yours faithfully,

For Zota Health Care Limited

Ashvin Variya

(Company Secretary & Compliance Officer)

Place: Surat

## Registered Office:

Zota House, 2/896, Hira Modi Street, Sagrampura, Surat - 395 002 | Ph: +91 261 2331601 Email: info@zotahealthcare.com Web: www.zotahealthcare.com

## Plant:

Plot no. 169, Surat Special Economic Zone, Nr. Sachin Railway Station, Sachin, Surat - 394 230 (Guj.) India Ph: +91 261 2397122

7

CIN: L24231GJ2000PLC038352